Strategies for the prevention of infection after solid organ transplantation

Expert Review of Anti-Infective Therapy

Volumn 4, Issue 5, 2006, Pages 837-852

  Hanson, Kimberly ^a   Alexander, Barbara ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Antimicrobial prophylaxis; Infection; Prevention; Solid organ; Transplantation

Indexed keywords

AMPHOTERICIN B; AMPHOTERICIN B LIPID COMPLEX; ANTIINFECTIVE AGENT; ATOVAQUONE; CEPHALOSPORIN DERIVATIVE; CHICKENPOX VACCINE; CIPROFLOXACIN; COTRIMOXAZOLE; CYCLOSPORIN; DAPSONE; DIPHTHERIA PERTUSSIS TETANUS VACCINE; DIPHTHERIA TETANUS TOXOID; FLUCONAZOLE; GANCICLOVIR; HEPATITIS A VACCINE; HEPATITIS B VACCINE; IMMUNOSUPPRESSIVE AGENT; INFLUENZA VACCINE; ISONIAZID; ITRACONAZOLE; PENTAMIDINE; PLACEBO; PNEUMOCOCCUS VACCINE; POLIOMYELITIS VACCINE; PYRIDOXINE; RIFAMPICIN; TACROLIMUS; UNINDEXED DRUG; VALACICLOVIR; VALGANCICLOVIR;

BACTERIAL INFECTION; CHICKENPOX; CLINICAL PROTOCOL; CLINICAL TRIAL; CYTOMEGALOVIRUS; DIPHTHERIA; DRUG POTENTIATION; EVIDENCE BASED MEDICINE; HEART TRANSPLANTATION; HEPATITIS A; HEPATITIS B; HEPATITIS B VIRUS; HERPES SIMPLEX VIRUS; HUMAN; HUMAN HERPESVIRUS 7; IMMUNIZATION; INFECTION; INFECTION PREVENTION; INFLUENZA; KIDNEY TRANSPLANTATION; LIVER TOXICITY; LIVER TRANSPLANTATION; LOW DRUG DOSE; LUNG TRANSPLANTATION; MORBIDITY; MORTALITY; MYCOSIS; NONHUMAN; ORGAN TRANSPLANTATION; PANCREAS TRANSPLANTATION; PARASITOSIS; PERIOPERATIVE PERIOD; PERTUSSIS; POLIOMYELITIS; POSTOPERATIVE CARE; PREOPERATIVE CARE; REVIEW; SEROLOGY; STREPTOCOCCUS INFECTION; STRONGYLOIDES STERCORALIS; TETANUS; TOXOPLASMA GONDII; TUBERCULOSIS; VIRUS INFECTION;

EID: 33845382036     PISSN: 14787210     EISSN: 17448336     Source Type: Journal    
DOI: 10.1586/14787210.4.5.837     Document Type: Review

References (159)

1. Rubin RH. The prevention and treatment of infectious disease in the transplant patient: where are we now and where do we need to go? Transpl. Infect. Dis. 6(1), 1-2 (2004).
2. Delmonico FL. Cadaver donor screening for infectious agents in solid organ transplantation. Clin. Infect. Dis. 31(3), 781-786 (2000).
3. Delmonico FL, Snydman DR. Organ donor screening for infectious diseases: review of practice and implications for transplantation. Transplantation 65(5), 603-610 (1998).
4. Anonymous. Screening of donor and recipient prior to solid organ transplantation. Am. J Transpl. 4(Suppl. 10), 10-20 (2004).
5. Schaffner A. Pretransplant evaluation for infections in donors and recipients of solid organs. Clin. Infect. Dis. 33(Suppl. 1), S9-S14 (2001).
6. Strong DM, Nelson K, Pierce M, Stramer SL. Preventing disease transmission blood for viral nucleic acid. Cell Tissue Bank 6(4), 255-262 (2005).
7. Singh N, Paterson DL. Mycobacterium tuberculosis infection in solid-organ transplant recipients: impact and implications for management. Clin. Infect. Dis. 27(5), 1266-1277 (1998).
8. Schluger LK, Sheiner PA, Jonas M et al. Isoniazid hepatotoxicity after orthotopic liver transplantation. Mt Sinai J. Med. 63(5-6), 364-369(1996).
9. Chaparro SV, Montoya JG, Keeffe EB, Rhee JT, Small PM. Risk of tuberculosis in tuberculin skin test-positive liver transplant patients. Clin. Infect. Dis. 29(1), 207-208 (1999).
10. Higgins RM, Cahn AP, Porter D et al. Mycobacterial infections after renal transplantation. Q. J. Med. 78(286), 145-153 (1991).
11. Qunibi WY, al-Sibai MB, Taher S et al. Mycobacterial Infection after renal transplantation-report of 14 cases and review of the literature. Q.J. Med. 77(282), 1039-1060 (1990).
12. American Thoracic Society. Targeted tuberculin testing and treatment of latent tuberculosis infection. Am. J. Respir. Crit. Care Med. 161(4), S221-S247 (2000).
13. Mazurek GH, Jereb J, Lobue P, lademarco MF, Metchock B, Vernon A. Guidelines for using the QuantiFERON-TB Gold test for detecting Mycobacterium tuberculosis infection, United States. MMWR Recomm. Rep. 54(RR-15),49-55 (2005).
14. Pirofski LA, Casadevall A. Use of licensed vaccines for active immunization of the immunocompromised host. Clin. Microbiol. Rev. 11(1), 1-26 (1998).
15. Avery RK, Ljungman P. Prophylactic measures in the solid-organ recipient before transplantation. Clin. Infect. Dis. 33(Suppl. 1), S15-S21 (2001).
16. Gardner P, Pickering LK, Orenstein WA, Gershon AA, Nichol KL. Guidelines for quality standards for immunization. Clin. Infect. Dis. 35(5), 503-511 (2002).
17. Duchini A, Goss JA, Karpen S, Pockros PJ. Vaccinations for adult solid-organ transplant recipients: current recommendations and protocols. Clin. Microbiol. Rev. 16(3), 357-364 (2003).
18. Cohen J, Rees AJ, Williams G. A prospective randomized controlled trial of perioperative antibiotic prophylaxis in renal transplantation. J. Hosp. Infect. 11(4), 357-363 (1988).
19. Kissel SM, Hoy WE, Freeman RB, Byer B, Yarger JM. Renal transplant urinary tract infections: effect of perioperative antibiotics and earlier catheter removal. NY State J. Med. 82(11), 1543-1545 (1982).
20. Villacian JS, Paya CV. Prevention of infections in solid organ transplant recipients. Transpl. Infect. Dis. 1(1), 50-64 (1999).
21. De SA, McDowell A, Archer L et al. Burkholderia cepacia complex genomovars and pulmonary transplantation outcomes in patients with cystic fibrosis. Lancet 358(9295), 1780-1781 (2001).
22. Maurer JR, Frost AE, Estenne M, Higenbottam T, Glanville AR. International guidelines for the selection of lung transplant candidates. The International Society for Heart and Lung Transplantation, the American Thoracic Society, the American Society of Transplant Physicians, the European Respiratory Society. Transplantation 66(7), 951-956 (1998).
23. Desai D, Desai N, Nightingale P, Elliott T, Neuberger J. Carriage of methicillin-resistant Staphylococcus aureus is associated with an increased risk of infection after liver transplantation. Liver Transpl. 9(7), 754-759 (2003).
24. McNeil SA, Malani PN, Chenoweth CE et al. Vancomycin-resistant enterococcal colonization and infection in liver transplant candidates and recipients: a prospective surveillance study. Clin. Infect. Dis. 42(2), 195-203 (2006).
25. Paterson DL, Rihs JD, Squier C, Gayowski T, Sagnimeni A, Singh N. Lack of efficacy of mupirocin in the prevention of infections with Staphylococcus aureus in liver transplant recipients and candidates. Transplantation 75(2), 194-198 (2003).
26. Bratzler DW, Houck PM. Antimicrobial prophylaxis for surgery: an advisory statement from the National Surgical Infection Prevention Project. Clin. Infect. Dis. 38(12), 1706-1715 (2004).
27. Mangram AJ, Horan TC, Pearson ML, Silver LC, Jarvis WR. Guideline for prevention of surgical site infection, 1999. Hospital Infection Control Practices Advisory Committee. Infect. Control Hosp. Epidemiol. 20(4), 250-278 (1999).
28. van der Waaji D. Colonization pattern of the digestive tract by potentially pathogenic microorganisms: colonization-controlling mechanisms and consequences for antibiotic treatment. Infection 11 (Suppl. 2), S90-S92 (1983).
29. Patel R, Paya CV. Infections in solid-organ transplant recipients. Clin. Microbiol. Rev. 10(1), 86-124 (1997).
30. Alexander BD, Tapson VF. Infectious complications of lung transplantation. Transpl. Infect. Dis. 3(3), 128-137 (2001).
31. Speich R, van der Bij W. Epidemiology and management of infections after lung transplantation. Clin. Infect. Dis. 33(Suppl. 1), S58-S65 (2001).
32. Ruiz I, Gavalda J, Monforte V et al. Donor-to-host transmission of bacterial and fungal infections in lung transplantation. Am. J. Transpl. 6(1), 178-182 (2006).
33. Chernish RN, Aaron SD. Approach to resistant Gram-negative bacterial pulmonary infections in patients with cystic fibrosis. Curr. Opin. Pulm. Med. 9(6), 509-515 (2003).
34. Lumbreras C, Lizasoain M, Moreno E et al. Major bacterial infections following liver transplantation: a prospective study. Hepatogastroenterology 39(4), 362-365 (1992).
35. van der Waaji D, Manson WL, Arends JP, de Vries-Hospers HG. Clinical use of selective decontamination: the concept. Intensive Care Med 16(Suppl. 3), S212-S216 (1990).
36. Gorensek MJ, Carey WD, Washington JA, Vogt DP, Broughan TA, Westveer MK. Selective bowel decontamination with quinolones and nystatin reduces Gram-negative and fungal infections in orthotopic liver transplant recipients. Cleve. Clin. J. Med. 60(2), 139-144 (1993).
37. Hjortrup A, Rasmussen A, Hansen BA et al. Early bacterial and fungal infections in liver transplantation after oral selective bowel decontamination. Transpl. Proc. 29(7), 3106-3110 (1997).
38. Kuo PC, Bartlett ST, Lim JW, Plotkin JS, Wilson S, Johnson LB. Selective bowel decontamination in hospitalized patients awaiting liver transplantation. Am. J. Surg. 174(6), 745-748 (1997).
39. Steffen R, Reinhartz 0, Blumhardt G et al. Bacterial and fungal colonization and infections using oral selective bowel decontamination in orthotopic liver transplantations. Transpl. Int. 7(2), 101-108 (1994).
40. Raakow R, Steffen R, Lefebre B, Bechstein WO, Blumhardt G, Neuhaus P. Selective bowel decontamination effectively prevents Gram-negative bacterial infections after liver transplantation. Transpl. Proc. 22(4), 1556-1557 (990).
41. Zwaveling JH, Maring JK, Klompmaker IJ et al. Selective decontamination of the digestive tract to prevent postoperative infection: a randomized placebo-controlled trial in liver transplant patients. Crit. Care Med. 30(6), 1204-1209 (2002).
42. Hellinger WC, Yao JD, Alvarez S et al. A randomized, prospective, double-blinded evaluation of selective bowel decontamination in liver transplantation. Transplantation 73(12), 1904-1909 (2002).
43. Arnow PM, Carandang GC, Zabner R, Irwin ME. Randomized controlled trial of selective bowel decontamination for prevention of infections following liver transplantation. Clin. Infect. Dis. 22(6), 997-1003 (1996).
44. Safdar N, Said A, Lucey MR. The role of selective digestive decontamination for reducing infection in patients undergoing liver transplantation: a systematic review and meta-analysis. Liver Transpl. 10(7), 817-827 (2004).
45. Patel R, Badley AD, Larson-Keller J et al. Relevance and risk factors of enterococcal bacteremia following liver transplantation. Transplantation 61(8), 1192-1197 (1996).
46. Patel R, Cockerill FR, Porayko MK, Ossnon DR, Ilstrup DM, Keating MR. Lactobacillemia in liver transplant patients. Clin. Infect. Dis. 18(2), 207-212 (1994).
47. Rayes N, Seehofer D, Muller AR, Hansen S, Bengmark S, Neuhaus P. Influence of probiotics and fibre on the incidence of bacterial infections following major abdominal surgery - results of a prospective trial. Z. Gastroenterol. 40(10), 869-876 (2002).
48. Rayes N, Seehofer D, Hansen S et al. Early enteral supply of lactobacillus and fiber versus selective bowel decontamination: a controlled trial in liver transplant recipients. Transplantation 74(1), 123-127 (2002).
49. Rayes N, Seehofer D, Theruvath T et al. Supply of pre- and probiotics reduces bacterial infection rates after liver transplantation - a randomized, double-blind trial. Am. J. Transpl. 5(1), 125-130 (2005).
50. Larson AM, Chan GC, Wartelle CF et al. Infection complicating percutaneous liver biopsy in liver transplant recipients. Hepatology 26(6), 1406-1409 (1997).
51. Montoya JG, Giraldo LF, Efron B et al. Infectious complications among 620 consecutive heart transplant patients at Stanford University Medical Center. Clin. Infect. Dis. 33(5), 629-640 (2001).
52. Smart FW, Naftel DC, Costanzo MR et al. Risk factors for early, cumulative, and fatal infections after heart transplantation: a multi-institutional study. J. Heart Lung Transplant. 15(4), 329-341 (1996).
53. Holman WL, Murrah CR, Ferguson ER, Bourge RC, McGiffin DC, Kirklin JK. Infections during extended circulatory support: University of Alabama at Birmingham experience 1989 to 1994. Ann. Thoracic Surg. 61(1), 366-371 (1996).
54. Moroney DA, Vaca KJ. Infectious complications associated with ventricular assist devices. Am. J. Crit. Care 4(3), 204-209 (1995).
55. Myers TJ, Khan T, Frazier OH. Infectious complications associated with ventricular assist systems. ASAIO J. 46(6), S28-S36 (2000).
56. Springer WE, Wasler A, Radovancevic B et al. Retrospective analysis of infection in patients undergoing support with left ventricular assist systems. ASAIO J. 42(5), M763-M765 (1996).
57. de Gevignev G, Pop C, Delahaye JP. The risk of infective endocarditis after cardiac surgical and interventional procedures. Eur. Heart J. 16(Suppl. B), 7-14 (1995).
58. Grossi P, De Maria R, Caroli A, Zaina MS, Minoli L. Infections in heart transplant recipients: the experience of the Italian heart transplantation program. Italian Study Group on Infections in Heart Transplantation. J. Heart Lung Transplant. 11(5), 847-866 (1992).
59. Dajani AS, Taubert KA, Wilson W et al. Prevention of bacterial endocarditis: recommendations by the American Heart Association. Clin. Infect. Dis. 25(6), 1448-1458(1997).
60. Muller V, Becker G, Delfs M, Albrecht KH, Philipp T, Heemann U. Do urinary tract infections trigger chronic kidney transplant rejection in man? J. Urol. 159(6), 1826-1829 (1998).
61. Chuang P, Parikh CR, Langone A. Urinary tract infections after renal transplantation: a retrospective review at two US transplant centers. Clin. Transplant. 19(2), 230-235 (2005).
62. Takai K, Aoki A, Suga A et al. Urinary tract infections following renal transplantation. Transplant. Proc. 30(7), 3140-3141 (1998).
63. Takai K, Tollemar J, Wilczek HE, Groth CG. Urinary tract infections following renal transplantation. Clin. Transplant. 12(1), 19-23 (1998).
64. Erturk E, Burzon DT, Orloff M, Rabinowitz R. Outcome of patients with vesicoureteral reflux after renal transplantation: the effect of pretransplantation surgery on posttransplant urinary tract infections. Urology 51 (Suppl. 5A), 27-30 (1998).
65. Lumbreras C, Fernandez I, Velosa J, Munn S, Sterioff S, Paya CV. Infectious complications following pancreatic transplantation: incidence, microbiological and clinical characteristics, and outcome. Clin. Infect. Dis. 20(3), 514-520 (1995).
66. Fox BC, Sollinger HW, Belzer FO, Maki DG. A prospective, randomized, double-blind study of trimethoprim-sulfamethoxazole for prophylaxis of infection in renal transplantation: clinical efficacy, absorption of trimethoprim-sulfamethoxazole, effects on the microflora, and the cost-benefit of prophylaxis. Am. J. Med. 89(3), 255-274 (1990).
67. Tolkoff-Rubin NE, Cosimi AB, Russell PS, Rubin RH. A controlled study of trimethoprim-sulfamethoxazole prophylaxis of urinary tract infection in renal transplant recipients. Rev. Infect. Dis. 4(2), 614-618 (1982).
68. Moyses NM, Costa RS, Reis MA et al. Use of ciprofloxacin as a prophylactic agent in urinary tract infections in renal transplant recipients. Clin. Transplant 11(5 Pt 1), 446-452 (1997).
69. Cahill BC, Hibbs JR, Savik K et al. Aspergillus airway colonization and invasive disease after lung transplantation. Chest 112(5), 1160-1164 (1997).
70. Nunley DR, Ohori P, Grgurich WF et al. Pulmonary aspergillosis in cystic fibrosis lung transplant recipients. Chest 114(5), 1321-1329 (1998).
71. O'Neill JM, Schutze GM, Heulitt MJ, Simpson PM, Taylor BJ. Nosocomial infections during extracorporeal membrane oxygenation. Intensive Care Med. 27(8), 1247-1253 (2001).
72. Dummer JS, Lazariashvilli N, Barnes J, Ninan M, Milstone AP. A survey of antifungal management in lung transplantation. J. Heart Lung Transplant. 23(12), 1376-1381 (2004).
73. Reichenspurner H, Gamberg P, Nitschke M et al. Significant reduction in the number of fungal infections after lung, heart-lung, and heart transplantation using aerosolized amphotericin B prophylaxis. Transpl. Proc. 29(1-2), 627-628 (1997).
74. Palmer SM, Drew RH, Whitehouse JD et al. Safety of aerosolized amphotericin B lipid complex in lung transplant recipients. Transplantation 72(3), 545-548 (2001).
75. Shitrit D, Ollech JE, Ollech A et al. Itraconazole prophylaxis in lung transplant recipients receiving tacrolimus (FK 506), efficacy and drug interaction. J. Heart Lung Transplant. 24(12), 2148-2152 (2005).
76. Hamacher J, Spiliopoulos A, Kurt AM, Nicod LP. Pre-emptive therapy with azoles in lung transplant patients. Geneva Lung Transplantation Group. Eur. Respir. J. 13(1), 180-186 (1999).
77. Anonymous. Fungal infections. Am. J. Transplant. 4(Suppl. 10), 110-134 (2004).
78. Paya CV. Fungal infections in solid-organ transplantation. Clin. Infect. Dis. 16(5), 677-688 (1993).
79. Paya CV. Prevention of fungal and hepatitis virus infections in liver transplantation. Clin. Infect. Dis. 33(Suppl. 1), S47-S52 (2001).
80. Singh N, Avery RK, Munoz P et al. Trends in risk profiles for and mortality associated with invasive aspergillosis among liver transplant recipients. Clin. Infect. Dis. 36(1), 46-52 (2003)
81. Lumbreras C, Cuervas-Mons V, Jara P et al. Randomized trial of fluconazole versus nystatin for the prophylaxis of Candida infection following liver transplantation. J. Infect. Dis. 174(3), 583-588 (1996).
82. Winston DJ, Pakrasi A, Busuttil RW. Prophylactic fluconazole in liver transplant recipients. A randomized, double-blind, placebo-controlled trial. Ann. Intern. Med. 131(10), 729-737 (1999).
83. Playford EG, Webster AC, Sorell TC, Craig JC. Antifungal agents for preventing fungal infections in solid organ transplant recipients. Cochrane Database Syst. Rev. (3), CD004291 (2004).
84. Tollemar J, Hockerstedt K, Ericzon BG, Jalanko H, Ringden O. Prophylaxis with liposomal amphotericin B (AmBisome) prevents fungal infections in liver transplant recipients: long-term results of a randomized, placebo-controlled trial. Transpl. Proc. 27(1), 1195-1198 (1995).
85. Singh N, Paterson DL, Gayowski T, Wagener MM, Marino IR. Preemptive prophylaxis with a lipid preparation of amphotericin B for invasive fungal infections in liver transplant recipients requiring renal replacement therapy. Transplantation 71(7), 910-913 (2001).
86. Singhal S, Ellis RW, Jones SG et al. Targeted prophylaxis with amphotericin B lipid complex in liver transplantation. Liver Transpl. 6(5), 588-595 (2000).
87. Sharpe MD, Ghent C, Grant D, Horbay GL, McDougal J, David CW. Efficacy and safety of itraconazole prophylaxis for fungal infections after orthotopic liver transplantation: a prospective, randomized, double-blind study. Transplantation 76(6), 977-983 (2003).
88. Winston DJ, Busuttil RW. Randomized controlled trial of oral itraconazole solution versus intravenous/oral fluconazole for prevention of fungal infections in liver transplant recipients. Transplantation 74(5), 688-695 (2002).
89. Singh N, Paterson DL. Aspergillus infections in transplant recipients. Clin. Microbiol. Rev. 18(1), 44-69 (2005).
90. Malani PN, Dyke DB, Pagani FD, Chenoweth CE. Nosocomial infections in left ventricular assist device recipients. Clin. Infect. Dis. 34(10), 1295-1300 (2002).
91. Skinner JL, Harris C, Aaron MF et al. Cost-benefit analysis of extended antifungal prophylaxis in ventricular assist devices. ASAIO J. 46(5), 587-589 (2000).
92. Benedetti E, Gruessner AC, Troppmann C et al. Intra-abdominal fungal infections after pancreatic transplantation: incidence, treatment, and outcome. J. Am. Coll. Surg. 183(4), 307-316 (1996).
93. Stratta RJ. Ganciclovir/acyclovir and fluconazole prophylaxis after simultaneous kidney-pancreas transplantation. Transpl. Proc. 30(2), 262 (1998).
94. Safdar N, Slattery WR, Knasinski V et al. Predictors and outcomes of candiduria in renal transplant recipients. Clin. Infect. Dis. 40(10), 1413-1421 (2005).
95. Fishman JA. Pneumocystis carinii and parasitic infections in transplantation. Infect. Dis. Clin. North Am. 9(4), 1005-1044 (1995).
96. Fishman JA. Treatment of infection due to Pneumocystis carinii. Antimicrob. Agents Chemother. 42(6), 1309-1314 (1998).
97. Fishman JA. Prevention of infection due to Pneumocystis carinii. Antimicrob. Agents Chemother. 42(5), 995-1004 (1998).
98. Fishman JA. Prevention of infection caused by Pneumocystis carinii in transplant recipients. Clin. Infect. Dis. 33(8), 1397-1405 (2001).
99. Falagas ME, Arbo M, Ruthazer R et al. Cytomegalovirus disease is associated with increased cost and hospital length of stay among orthotopic liver transplant recipients. Transplantation 63(11), 1595-1601 (1997).
100. Paya CV. Economic impact of cytomegalovirus in solid organ transplantation. Transpl. Infect. Dis. 3(Suppl. 2), 14-19 (2001).
101. Fateh-Moghadam S, Bocksch W, Wessely R, Jager G, Hetzer R, Gawaz M. Cytomegalovirus infection status predicts progression of heart-transplant vasculopathy. Transplantation 76(10), 1470-1474 (2003).
102. Paya CV. Indirect effects of CMV in the solid organ transplant patient. Transpl. Infect. Dis. 1 (Suppl. 1), 8-12 (1999).
103. Paya CV. Prevention of cytomegalovirus disease in recipients of solid-organ transplants. Clin. Infect. Dis. 32(4), 596-603 (2001).
104. Paya C, Humar A, Dominguez E et al. Efficacy and safety of valganciclovir vs. oral ganciclovir for prevention of cytomegalovirus disease in solid organ transplant recipients. Am. J. Transplant. 4(4), 611-620 (2004).
105. Jain A, Orloff M, Kashyap R et al. Does valganciclovir hydrochloride (valcyte) provide effective prophylaxis against cytomegalovirus infection in liver transplant recipients? Transpl. Proc. 37(7), 3182-3186 (2005).
106. Humar A, Kumar D, Preiksaitis J et al. A trial of valganciclovir prophylaxis for cytomegalovirus prevention in lung transplant recipients. Am. J. Transplant. 5(6), 1462-1468 (2005).
107. Zamora MR, Nicolls MR, Hodges TN et al. Following universal prophylaxis with intravenous ganciclovir and cytomegalovirus immune globulin, valganciclovir is safe and effective for prevention of CMV infection following lung transplantation. Am. J. Transplant. 4(10), 1635-1642 (2004).
108. Boivin G, Goyette N, Gilbert C et al. Absence of cytomegalovirus-resistance mutations after valganciclovir prophylaxis, in a prospective multicenter study of solid-organ transplant recipients. J. Infect. Dis. 189(9), 1615-1618 (2004).
109. Boivin G, Goyette N, Gilbert C, Humar A, Covington E. Clinical impact of ganciclovir-resistant cytomegalovirus infections in solid organ transplant patients. Transpl. Infect. Dis. 7(3-4), 166-170 (2005).
110. Boivin G, Erice A, Crane DD, Dunn DL, Balfour HH Jr. Ganciclovir susceptibilities of cytomegalovirus (CMV isolates from solid organ transplant recipients with CMV viremia after antiviral prophylaxis. J. Infect. Dis. 168(2), 332-335 (1993).
111. Paya CV, Wilson JA, Espy MJ et al. Preemptive use of oral ganciclovir to prevent cytomegalovirus infection in liver transplant patients: a randomized, placebo-controlled trial. J. Infect. Dis. 185(7), 854-860 (2002).
112. Singh N. Preemptive therapy versus universal prophylaxis with ganciclovir for cytomegalovirus in solid organ transplant recipients. Clin. Infect. Dis. 32(5), 742-751 (2001).
113. Kalil AC, Levitsky J, Lyden E, Stoner J, Freifeld AG. Meta-analysis: the efficacy of strategies to prevent organ disease by cytomegalovirus in solid organ transplant recipients. Ann. Intern. Med. 143(12), 870-880 (2005).
114. Strippoli GF, Hodson EM, Jones C, Craig JC. Preemptive treatment for cytomegalovirus viremia to prevent cytomegalovirus disease in solid organ transplant recipients. Transplantation 81(2), 139-145 (2006).
115. Sia IG, Patel R. New strategies for prevention and therapy of cytomegalovirus infection and disease in solid-organ transplant recipients. Clin. Microbiol. Rev. 13(1), 83-121 (2000).
116. Preiksaitis JK, Brennan DC, Fishman J, Allen U. Canadian society of transplantation consensus workshop on cytomegalovirus management in solid organ transplantation final report. Am. J. Transplant. 5(2), 218-227 (2005).
117. Zamora MR, Davis RD, Leonard C. Management of cytomegalovirus infection in lung transplant recipients: evidence-based recommendations. Transplantation 80(2), 157-163 (2005).
118. az-Pedroche C, Lumbreras C, Del VP et al. Efficacy and safety of valgancyclovir as preemptive therapy for the prevention of cytomegalovirus disease in solid organ transplant recipients. Transplant. Proc. 37(9), 3766-3767 (2005).
119. Singh N, Wannstedt C, Keyes L, Gayowski T, Wagener MM, Cacciarelli TV. Efficacy of valganciclovir administered as preemptive therapy for cytomegalovirus disease in liver transplant recipients: impact on viral load and late-onset cytomegalovirus disease. Transplantation 79(1), 85-90 (2005).
120. Mattes FM, Hainsworth EG, Hassan-Walker AF et al. Kinetics of cytomegalovirus load decrease in solid-organ transplant recipients after preemptive therapy with valganciclovir. J. Infect. Dis. 191(1), 89-92 (2005).
121. Sia IG, Wilson JA, Groettum CM, Espy MJ, Smith TF, Paya CV. Cytomegalovirus (CMV) DNA load predicts relapsing CMV infection after solid organ transplantation. J. Infect. Dis. 181(2), 717-720 (2000).
122. Humar A, Kumar D, Boivin G, Caliendo AM. Cytomegalovirus (CMV) virus load kinetics to predict recurrent disease in solid-organ transplant patients with CMV disease. J. Infect. Dis. 186(6), 829-833 (2002).
123. Singh N, Dummer JS, Kusne S et al. Infections with cytomegalovirus and other herpes viruses in 121 liver transplant recipients: transmission by donated organ and the effect of OKT3 antibodies. J. Infect. Dis. 158(1), 124-131 (1988).
124. Slifkin M, Doron S, Snydman DR. Viral prophylaxis in organ transplant patients. Drugs 64(24), 2763-2792 (2004).
125. Lowance D, Neumayer HH, Legendre CM et al. Valacyclovir for the prevention of cytomegalovirus disease after renal transplantation. International Valacyclovir Cytomegalovirus Prophylaxis Transplantation Study Group. N. Engl. J. Med. 340(19), 1462-1470 (1999).
126. Anonymous. Epstein-Barr virus and lymphoproliferative disorders after transplantation. Am. J. Transplant. 4(Suppl. 10), 59-65 (2004).
127. Razonable RR, Paya CV. Herpes virus infections in transplant recipients: current challenges in the clinical management of cytomegalovirus and Epstein-Barr virus infections. Herpes 10(3), 60-65 (2003).
128. Funch DP, Walker AM, Schneider G, Ziyadeh NJ, Pescovitz MD. Ganciclovir and acyclovir reduce the risk of post-transplant lymphoproliferative disorder in renal transplant recipients. Am. J. Transplant. 5(12), 2894-2900 (2005).
129. Malouf MA, Chhajed PN, Hopkins P, Plit M, Turner J, Glanville AR. Anti-viral prophylaxis reduces the incidence of lymphoproliferative disease in lung transplant recipients. J. Heart Lung Transplant. 21(5), 547-554 (2002).
130. Green M, Reyes J, Webber S, Rowe D. The role of antiviral and immunoglobulin therapy in the prevention of Epstein-Barr virus infection and post-transplant lymphoproliferative disease following solid organ transplantation. Transplant. Infect. Dis. 3(2), 97-103 (2001).
131. Darenkov LA, Marcarelli MA, Basadonna GP et al. Reduced incidence of Epstein-Barr virus-associated posttransplant lymphoproliferative disorder using preemptive antiviral therapy. Transplantation 64(6), 848-852 (1997).
132. Davis CL, Harrison KL, McVicar JP et al. Antiviral prophylaxis and the Epstein Barr virus-related post-transplant lymphoproliferative disorder. Clin. Transplant 9(1), 53-59 (1995).
133. Humar A, Hebert D, Davies HD et al. A randomized trial of ganciclovir versus ganciclovir plus immune globulin for prophylaxis against Epstein-Barr virus related posttransplant lymphoproliferative disorder. Transplantation 81(6), 856-861 (2006).
134. Lee TC, Savoldo B, Rooney CM et al. Quantitative EBV viral loads and immunosuppression alterations can decrease PTLD incidence in pediatric liver transplant recipients. Am. J. Transplant. 5(9), 2222-2228 (2005).
135. Scheenstra R, Verschuuren EA, de Haan A et al. The value of prospective monitoring of Epstein-Barr virus DNA in blood samples of pediatric liver transplant recipients. Transpl. Infect. Dis. 6(1), 15-22 (2004).
136. Wagner HJ, Cheng YC, Huls MH et al. Prompt versus preemptive intervention for EBV lymphoproliferative disease. Blood 103(10), 3979-3981 (2004).
137. Singh N. Human herpesviruses-6, -7 and -8 in organ transplant recipients. Clin. Microbiol. Infect. 6(9), 453-459 (2000).
138. Singh N, Carrigan DR, Gayowski T, Marino IR. Human herpesvirus-6 infection in liver transplant recipients: documentation of pathogenicity. Transplantation 64(5), 674-678 (1997).
139. Mendez JC, Dockrell DH, Espy MJ et al. Human β-herpesvirus interactions in solid organ transplant recipients. J. Infect. Dis. 183(2), 179-184 (2001).
140. Dockrell DH, Prada J, Jones MF et al. Seroconversion to human herpesvirus 6 following liver transplantation is a marker of cytomegalovirus disease. J. Infect. Dis. 176(5), 1135-1140 (1997).
141. Yoshida M, Yamada M, Tsukazaki T et al. Comparison of antiviral compounds against human herpesvirus 6 and 7. Antiviral Res. 40(1-2), 73-84 (1998).
142. Galarraga MC, Gomez E, de Ona M et al. Influence of ganciclovir prophylaxis on cytomegalovirus, human herpesvirus 6, and human herpesvirus 7 viremia in renal transplant recipients. Tranpl. Proc. 37(5), 2124-2126 (2005).
143. - organ donors. Transplantation 59(2), 230-234 (1995).
144. Dominguez M, Barcena R, Garcia M, Lopez-Sanroman A, Nuno J. Vaccination against hepatitis B virus in cirrhotic patients on liver transplant waiting list. Liver Transplant. 6(4), 440-442 (2000).
145. Engler SH, Sauer PW, Golling M et al. Immunogenicity of two accelerated hepatitis B vaccination protocols in liver transplant candidates. Eur. J. Gastroenterol. Hepatol. 13(4), 363-367 (2001).
146. Kallinowski B, Benz C, Buchholz L, Stremmel W. Accelerated schedule of hepatitis B vaccination in liver transplant candidates. Transpl. Proc. 30(3), 797-799 (1998).
147. Chung RT, Feng S, Delmonico FL. Approach to the management of allograft recipients following the detection of hepatitis B virus in the prospective organ donor. Am. J. Transplant. 1(2), 185-191 (2001).
148. Suehiro T, Shimada M, Kishikawa K et al. Prevention of hepatitis B virus infection from hepatitis B core antibody-positive donor graft using hepatitis B immune globulin and lamivudine in living donor liver transplantation. Liver Internat. 25(6), 1169-1174 (2005).
149. Wang ZF, Zhu ZJ, Shen ZY. Advances in prophylaxis and treatment of recurrent hepatitis B after liver transplantation. Hepatobiliary Pancreat. Dis. Int. 4(4), 509-514 (2005).
150. Terrault N, Roche B, Samuel D. Management of the hepatitis B virus in the liver transplantation setting: a European and an American perspective. Liver Transpl. 11(7), 716-732 (2005).
151. Mohanty SR, Cotler SJ. Management of hepatitis B in liver transplant patients. J. Clin. Gastroenterol. 39(1), 58-63 (2005).
152. Seehofer D, Rayes N, Neuhaus P. Prophylaxis and treatment of hepatitis B recurrence after liver transplantation in the antiviral era. Exp. Rev. Anti Infect. Ther. 1(2), 307-318 (2003).
153. Roche B, Samuel D. Evolving strategies to prevent HBV recurrence. Liver Transplant. 10(10 Suppl. 2), S74-S85 (2004).
154. Schreibman IR, Schiff ER. Prevention and treatment of recurrent hepatitis B after liver transplantation: the current role of nucleoside and nucleotide analogues. Ann. Clin. Microbiol, Antimicrob. 5, 8 (2006).
155. Baden LR, Katz JT, Franck L et al. Successful toxoplasmosis prophylaxis after orthotopic cardiac transplantation with trimethoprim-sulfamethoxazole. Transplantation 75(3), 339-343 (2003).
156. Stone WJ, Schaffner W. Strongyloides infections in transplant recipients. Semin. Respir. Infect. 5(1), 58-64 (1990).
157. Palau LA, Pankey GA. Strongyloides hyperinfection in a renal transplant recipient receiving cyclosporine: possible Strongyloides stercoralis transmission by kidney transplant. Am. J. Trop. Med. Hyg. 57(4), 413-415 (1997).
158. Immunosuppressive drug interactions with anti-infective agents. Am. J. Transplant. 4(Suppl. 10), 164-166 (2004).
159. Strategies for safe living following solid organ transplantation. Am. J. Transplant. 4(Suppl. 10), 156-159 (2004).